Portland, OR -- (SBWIRE) -- 09/18/2017 -- Cholera is a chronic disease associated with diarrhea and immediate treatment is essential as death is inevitable if the disease is left untreated. Cholera is an acute infection caused by the bacterium Vibrio cholerae. It is anticipated to be a global threat to public health especially in regions that lack social development. Thus, oral cholera vaccines are utilized to supplement the management of the disease globally.
The factors that fuel the growth of the global Whole Cell Cholera Vaccine (recombinant B-subunit) Market are rising incidence of cholera among people in endemic regions along with a lack of sanitation and hygiene in certain countries. In addition, according to WHO in 2015, cholera was responsible for 21,000 to 143,000 deaths globally. However, longer timelines required to produce vaccines and high monetary inputs associated with the same restrain the market growth. But recent outbreaks of cholera in certain countries will offer lucrative opportunities for the market growth.
Get PDF Brochure of this report: https://www.alliedmarketresearch.com/request-toc-and-sample/3798
The market is segmented based on end user and region. Based on end user, the market is segmented into pediatrics and adults. Based on region, it has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.
-The study provides an in-depth analysis of the global whole cell cholera vaccine (recombinant B-subunit) market with current trends and future estimations to elucidate imminent investment pockets.
-It presents a quantitative analysis from 2016 to 2023 to enable stakeholders to capitalize on prevailing market opportunities.
-Key players have been profiled and their strategies thoroughly analyzed, which predict the competitive outlook of the market.
Early buyers will receive 20% customization on this report